Bevacizumab in recurrent high-grade pediatric gliomas.

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promise in treating recurrent adult high-grade glioma (HGG). However, there is very little data on recurrent or progressive pediatric HGG treated with bevacizumab. We report the results of a single institution experience using bevacizumab and irinotecan in children who… (More)
DOI: 10.1093/neuonc/noq033

Topics

  • Presentations referencing similar topics